Archivio istituzionale della ricerca dell'Università degli Studi di Palermo
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, pubblicazioni, progetti, attività) adottato dall’Università di Palermo, e ha lo scopo di raccogliere, conservare, documentare, e diffondere ad accesso aperto le informazioni relative alla produzione scientifica degli autori afferenti all’Ateneo.
EnglishPrevious article in issueNext article in issue Introduction: There is a limited documentation about the retreatment of patients failing a recommended NS5A-containing regimen in Italy. Materials & methods: Within the VIRONET-C network, 386 NS5A-failing patients infected with different HCV-genotypes (GT) (GT1a/1b/2a-c/3a-b-g-h/4a-d-n-o-v=93/124/19/112/38) were analyzed. Retreatment of 105 failures was investigated. HCV-resistance-test was performed by Sanger-sequencing. Results: Failures following seven different NS5A-containing regimens were studied: 3D/2D (paritaprevir/ombitasvir ± dasabuvir) ± ribavirin (N = 72/4), daclatasvir/ledipasvir/velpatasvir + sofosbuvir ± ribavirin (N = 105/131/20), grazoprevir/elbasvir ± ribavirin (N = 34), glecaprevir/pibrentasvir (N = 20). Notably, 18.1% of NS5A-failing patients did not show any resistance-associated-substitutions (RAS), while 81.9% showed at least one NS5A-RAS, with multiclass-resistance in 35.5%. NS5A-RAS were observed more frequently in glecaprevir/pibrentasvir failures (GT1a 83.3%: Y93H + Q30H/D or +H58D; GT3a: 83.3% Y93H + A30K/G or +L31I) compared to sofosbuvir/velpatasvir (GT1a 16.6%: Y93H + Q30H, p = 0.08; GT3a 20.0%: Y93H/N + A30K/T, p = 0.03). To date, 105 failures have started a retreatment: sofosbuvir/velpatasvir ± ribavirin (N = 30), sofosbuvir/velpatasvir/voxilaprevir ± ribavirin (N = 67), glecaprevir/pibrentasvir (N = 4), grazoprevir/elbasvir ± sofosbuvir + ribavirin (N = 3), 3D + sofosbuvir + ribavirin (N = 1). The majority of patients were cirrhotic (51.9%) and relapsers (87.5%). The prevalence of NS5A-RASs before retreatment was 80.9%, with multiclass-resistance 29.5%. Among patients completing post-retreatment follow-up, a sustained-viral-response at week 12 (SVR12) was observed in 26/33 (78.8%). SVR4 was documented in 49/56 (87.5%). SVR12 was 76.0% with sofosbuvir/velpatasvir ± ribavirin (N = 25). Differently, SVR12 was 100% with glecaprevir/pibrentasvir for 8/12/16 weeks (N = 3), grazoprevir/elbasvir ± sofosbuvir + ribavirin for 12/24 weeks (N = 3) or 3D + sofosbuvir + ribavirin for 24 weeks (N = 1), despite the presence of NS5A-RASs. Until now, 67 patients started sofosbuvir/velpatasvir/voxilaprevir ± ribavirin recommended-retreatment for 12 weeks. 54/67 (80.6%) showed at least one baseline NS5A-RAS, 23/67 (34.3%) multiple-NS5A-RASs, and 22/67 (32.8%) multiclass-resistance. Of 25 patients with available outcome, 96.0% had SVR4. Only 1 GT1b infected patient was non-responder, without RASs before retreatment. Conclusions: In this real-life setting, NS5A-RASs were frequently detected at failure, and multiclass-resistance was around 30%. Overall, SVR after resistance-test-guided retreatment was >95%, with the exception of the sofosbuvir/velpatasvir retreatment. Our results show how HCV resistance-test at failure may be useful to optimize retreatment strategies.
Di Maio, V., Aragri, M., Masetti, C., Paolucci, S., Bruzzone, B., Degasperi, E., et al. (2019). Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience. In 52nd Annual Meeting of the Italian Association for the Study of the Liver – A.I.S.F. (pp.e53-e54).
| Autori: | Di Maio, V.; Aragri, M.; Masetti, C.; Paolucci, S.; Bruzzone, B.; Degasperi, E.; Barbaliscia, S.; Pollicino, T.; Minichini, C.; Calvaruso, V.; Rendina, M.; Cento, V.; Teti, E.; Micheli, V.; Ghisetti, V.; Polilli, E.; Palitti, V.; Landonio, S.; Lenci, I.; Donnarumma, L.; Nicolini, L.; Bertoli, A.; Starace, M.; Pasquazzi, C.; Callegaro, A.; Morisco, F.; Cenderello, G.; Marenco, S.; Gulminetti, R.; Novati, S.; Guarneri, V.; Andreone, P.; Galli, S.; Ciancio, A.; Sangiovanni, V.; Cuomo, N.; Raddi, A.; Morsica, G.; Borghi, V.; Maida, I.; Brunetto, M.; Colombatto, P.; Cozzolongo, R.; De Santis, A.; Lichtner, M.; Babudieri, S.; Taliani, G.; Santantonio, T.; Di Stefano, M.; Paternoster, C.; Ganga, R.; Puoti, M.; Rizzardini, G.; Pellicelli, A.; Milano, E.; Mastroianni, C.; Licata, A.; Di Lorenzo, F.; Giorgini, A.; Lampertico, P.; Parruti, G.; Coppola, N.; Zazzi, M.; Raimondo, G.; Andreoni, M.; Craxì, A.; Angelico, M.; Perno, C.; Ceccherini-Silberstein, F. |
| Titolo: | Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience |
| Data di creazione: | 2019-02 |
| Nome del convegno: | Part of special issue: 52nd Annual Meeting of the Italian Association for the Study of the Liver – A.I.S.F. |
| Luogo del convegno: | Roma |
| Anno del convegno: | 21-22 febbraio |
| Numero del convegno: | 51 |
| Data di pubblicazione: | 2019 |
| Numero di pagine: | 1 |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.dld.2018.11.139 |
| Citazione: | Di Maio, V., Aragri, M., Masetti, C., Paolucci, S., Bruzzone, B., Degasperi, E., et al. (2019). Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience. In 52nd Annual Meeting of the Italian Association for the Study of the Liver – A.I.S.F. (pp.e53-e54). |
| Tipologia: | 0 - Proceedings (TIPOLOGIA NON ATTIVA) |
| Appare nelle tipologie: | 0 - Proceedings (TIPOLOGIA NON ATTIVA) |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| 1-s2.0-S1590865818314105-Piter resistance.pdf | N/A | Administrator Richiedi una copia |
Copyright © 2021